AbbVie Completes New Licensing Agreement to Address Growing Demand for HIV Treatments in AfricaAbbVie and the Medicines Patent Pool (MPP) have completed a new licensing agreement to address future demands for HIV-1 treatment Lopinavir/Ritonavir (LPV/r) in South Africa and across Africa. The agreement has been reached to help ensure sustainable, long-term supply of LPV/r in South Africa and the African continent. LPV/r is a component of the most widely used HIV-1 treatment for second-line patients in the region. Our company is committed to providing treatment to people living with HIV and believes that Africa’s increased HIV testing efforts requires a strategy which is appropriate for Africa. AbbVie has a longstanding and ongoing commitment to people living with HIV-1 worldwide.
Read the announcement from the MPP here.
For further information please contact:
For Africa Media Inquiries:
For Global Media Inquiries: